[1] Mahata SK, Mahata M, Taylor C V L, et al. The Novel Catecholamine Release-Inhibitory Peptide Catestatin (Chromogranin A344-364)[M]. Springer, 2002, 263-277. [2] AngeloneT, Quintieri AM, BrarBK, et al. The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism[J]. Endocrinol, 2008, 149(10):4780-4793. [3] O'Connor DT, KailasamMT, Kennedy BP, et al. Early decline in thecatecholamine release-inhibitory peptidecatestatin in humans at geneticrisk of hypertension[J]. J Hypertens, 2002, 20(7):1335-1345. [4] James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults:report from the panel members appointed to the Eighth Joint National Committee (JNC 8)[J]. JAMA, 2014, 311(5):507-520. [5] 戴勇, 彭武建, 徐卓佳, 等. "两肾一夹"肾性高血压大鼠模型的改进[J]. 实验动物科学与管理, 2006, 23(2):60-62. [6] 刘洁, 白桦, 李丽, 等. 肾性和自发性高血压大鼠心肌肥大前后心肌Gαq/11含量的变化[J]. 中国应用生理学杂志, 2003, 19(2):200-201. [7] Campos RR, Oliveira-Sales E, Nishi EE, et al. Mechanisms of renal sympathetic activation in renovascular hypertension Experimental[J]. Exp Physiol, 2015, 100(5):496-501. [8] Gaede AH, Lung MS, Pilowsky PM. Catestatin attenuates the effects of intrathecalnicotine and isoproterenol[J]. Brain Res, 2009, 1305:86-95. [9] Bassino E, Fornero S, Gallo MP, et al. A novel catestatin-induced antiadrenergic mechanism triggered by the endothelial PI3K-eNOS pathway in the myocardium[J]. Cardiovasc Res, 2011, 91(4):617-624. [10] Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension:role of eNOS and oxidant stress[J]. Hypertension, 2004, 44(2):186-190. |